Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%

Toward More Inclusive, Accessible Clinical Trial Consent Forms

Spine Stereotactic Radiosurgery: A Critical Evaluation of the Evidence to Guide Clinical Practice

Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq

Ticiana Leal, MD, Moves to Emory University School of Medicine

Balancing the Benefits and Harms of Lung Cancer Screening

The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer

Adoption of VATS Continues to Vary Globally

First New Second-line Therapy for SCLC in Australia in 20 Years

Sotorasib Scores Second-line Approval in Canada

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

Question Literature’s Face Value